Kiwi Biosciences Analysis: $130K Raised
What is Kiwi Biosciences?
FODZYME sells a tasteless powder that breaks down common FODMAP triggers before eating. The company says it was founded by an IBS sufferer, developed with Harvard-trained scientists, and backed by peer-reviewed studies and patent-pending enzyme work. Its core product targets fructan, GOS, and lactose, with clinician resources and consumer kits built around low-FODMAP eating.
Location
Cambridge, United States
Employees
11-50
Founded
2020
Revenue
$1.2M
Business Model
Direct-to-consumer sales model with revenue from product sales and partnerships.
Product Features & Capabilities
- FODZYME® enzyme blend, home kit, on-the-go kit, anywhere bundle, aids in digestion of foods high in FODMAPs, allows enjoyment of meals without discomfort.
Pricing
- Home Kit: From $65.00
- On-the-Go Kit: From $65.00
- Anywhere Bundle: From $119.00
How much Kiwi Biosciences raised
1 - $0.13M
2020Lead Investor: Y Combinator, North South Ventures
Who are the founders of Kiwi Biosciences
AL
Anjie Liu
Founder
DH
David Hachuel Gurska
Founder
Competitors Overview
Kiwi Biosciences, which develops FODZYME®, faces competition from several companies in the digestive health market, particularly those focusing on FODMAP digestion. Key competitors include:
-
Casa de Sante: This company offers Low FODMAP Certified Digestive Enzymes, specifically designed for individuals with IBS and other digestive disorders. Their products are notable for being certified low FODMAP, which may appeal to consumers looking for assurance regarding FODMAP content.
-
Symprove: Known for its probiotic drinks, Symprove targets gut health and offers a different approach compared to enzyme supplements. Their products focus on delivering live bacteria to support gut health, which may attract customers looking for probiotic solutions rather than enzyme-based ones.
-
Beano: While not specifically targeted at FODMAPs, Beano is a well-known digestive enzyme supplement that helps break down complex carbohydrates. It may be seen as a more general solution for digestive discomfort, but it does not specifically address FODMAPs like FODZYME does.
-
FODMAP Digesting Enzymes (FodShop): This product line includes various enzyme supplements aimed at breaking down FODMAPs, similar to FODZYME. They emphasize a patent-pending formula that targets specific FODMAP triggers.
Notable differences include FODZYME's unique formulation that specifically targets fructans, GOS, and lactose, which are common FODMAP triggers. Additionally, FODZYME is marketed as a powder for maximum effectiveness during digestion, which may provide an advantage in terms of user experience and efficacy.
Investors
- Acacia Venture Capital Partners
- Jude Gomila
- Emily Leproust
- (Additional investors not specified)
Market Focus
Kiwi Biosciences primarily focuses on the health and wellness industry, specifically in the area of digestive health through the development of enzyme products that aid in the digestion of FODMAP-rich foods.
See something that needs updating? Suggest edits to this profile.